查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球類風濕性關節炎藥物市場：增長、未來展望、競爭分析 (2022-2030)
市場調查報告書
商品編碼
1184721

全球類風濕性關節炎藥物市場：增長、未來展望、競爭分析 (2022-2030)

Rheumatology Arthritis Therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日期: | 出版商: Acute Market Reports | 英文 115 Pages | 商品交期: 最快1-2個工作天內

價格

在 2022 年至 2030 年的預測期內，全球類風濕性關節炎治療市場預計將以 5% 的複合年增長率增長。 類風濕性關節炎發病率的增加正在推動類風濕性關節炎治療行業的擴張。 發達經濟體越來越多地採用生物製藥和明確的監管要求也有望支持市場擴張。 此外，人們對早期發現和治療風濕病症狀的認識不斷提高，以及在治療各種疾病時增加使用緩解疾病的抗風濕藥 (DMARD) 也是推動市場增長的主要因素。

本報告研究和分析了全球類風濕性關節炎藥物市場，提供了市場趨勢、市場驅動和製約因素、細分市場和區域分析以及主要公司概況等信息。

內容

第一章前言

第 2 章執行摘要

  • 市場快照：全球類風濕性關節炎藥物市場
  • 全球類風濕性關節炎藥物市場：按疾病類型分類（2021 年）
  • 全球類風濕性關節炎藥物市場：按藥物類型分類（2021 年）
  • 全球類風濕性關節炎藥物市場：按給藥方法分類（2021 年）
  • 全球類風濕性關節炎藥物市場：按銷售模式分類（2021 年）
  • 全球類風濕性關節炎藥物市場：按最終用戶分類（2021 年）
  • 全球類風濕性關節炎藥物市場：按地區劃分（2021 年）
  • 按地區劃分的有吸引力的投資提案（2021 年）

第 3 章類風濕性關節炎藥物市場：競爭分析

  • 主要類風濕性關節炎藥物市場供應商的市場定位
  • 供應商在類風濕性關節炎藥物市場上採用的策略
  • 主要行業戰略
  • 分層分析：2021 年與 2030 年

第 4 章類風濕性關節炎藥物市場：宏觀分析和市場動態

  • 簡介
  • 類風濕性關節炎藥物的全球市場價值（2020 年至 2030 年）
  • 市場動態
    • 市場驅動因素
    • 市場製約因素
    • 主要問題
    • 主要機會
  • 促進因素和抑制因素的影響分析
  • 蹺蹺板分析

第 5 章類風濕性關節炎藥物市場：按疾病類型分類（2020-2030 年）

  • 市場概覽
  • 增長和收益分析：2021 年與 2030 年
  • 市場細分
    • 骨關節炎
    • 強直性脊柱炎
    • 類風濕性關節炎
    • 痛風
    • 銀屑病關節炎
    • 反應性關節炎
    • 纖維肌痛
    • 硬皮病
    • 其他

第 6 章類風濕性關節炎藥物市場：按藥物類型分列 (2020-2030)

  • 市場概覽
  • 增長和收益分析：2021 年與 2030 年
  • 市場細分
    • 醫藥
    • 生物製藥
    • 生物仿製藥

第 7 章類風濕性關節炎藥物市場：按給藥方法（2020-2030 年）

  • 市場概覽
  • 增長和收益分析：2021 年與 2030 年
  • 市場細分
    • 本地
    • 口語
    • 腸外

第 8 章類風濕性關節炎藥物市場：按分銷模式（2020-2030 年）

  • 市場概覽
  • 增長和收益分析：2021 年與 2030 年
  • 市場細分
    • 處方藥
    • 非處方藥

第 9 章類風濕性關節炎藥物市場：按最終用戶分類（2020-2030 年）

  • 市場概覽
  • 增長和收益分析：2021 年與 2030 年
  • 市場細分
    • 醫院
    • 醫務室
    • 在線渠道
    • 零售渠道

第 10 章北美類風濕性關節炎藥物市場（2020-2030 年）

  • 市場概覽
  • 類風濕性關節炎藥物市場：按疾病類型分類（2020 年至 2030 年）
  • 類風濕性關節炎藥物市場：按藥物類型分類（2020 年至 2030 年）
  • 類風濕性關節炎藥物市場：按給藥方式分類（2020 年至 2030 年）
  • 類風濕性關節炎藥物市場：按銷售模式分類（2020-2030 年）
  • 類風濕性關節炎藥物市場：按最終用戶分類（2020-2030 年）
  • 按地區劃分的類風濕性關節炎藥物市場（2020 年至 2030 年）
    • 北美

第 11 章英國和歐盟類風濕性關節炎藥物市場 2020-2030

  • 市場概覽
  • 類風濕性關節炎藥物市場：按疾病類型分類（2020 年至 2030 年）
  • 類風濕性關節炎藥物市場：按藥物類型分類（2020 年至 2030 年）
  • 類風濕性關節炎藥物市場：按給藥方式分類（2020 年至 2030 年）
  • 類風濕性關節炎藥物市場：按銷售模式分類（2020-2030 年）
  • 類風濕性關節炎藥物市場：按最終用戶分類（2020-2030 年）
  • 按地區劃分的類風濕性關節炎藥物市場（2020 年至 2030 年）
    • 英國/歐盟

第12章亞太類風濕性關節炎藥物市場（2020-2030）

  • 市場概覽
  • 類風濕性關節炎藥物市場：按疾病類型分類（2020 年至 2030 年）
  • 類風濕性關節炎藥物市場：按藥物類型分類（2020 年至 2030 年）
  • 類風濕性關節炎藥物市場：按給藥方式分類（2020 年至 2030 年）
  • 類風濕性關節炎藥物市場：按銷售模式分類（2020-2030 年）
  • 類風濕性關節炎藥物市場：按最終用戶分類（2020-2030 年）
  • 按地區劃分的類風濕性關節炎藥物市場（2020 年至 2030 年）
    • 亞太地區

第 13 章拉丁美洲類風濕性關節炎藥物市場（2020-2030 年）

  • 市場概覽
  • 類風濕性關節炎藥物市場：按疾病類型分類（2020 年至 2030 年）
  • 類風濕性關節炎藥物市場：按藥物類型分類（2020 年至 2030 年）
  • 類風濕性關節炎藥物市場：按給藥方式分類（2020 年至 2030 年）
  • 類風濕性關節炎藥物市場：按銷售模式分類（2020-2030 年）
  • 類風濕性關節炎藥物市場：按最終用戶分類（2020-2030 年）
  • 按地區劃分的類風濕性關節炎藥物市場（2020 年至 2030 年）
    • 拉丁美洲

第 14 章中東和非洲類風濕性關節炎藥物市場 2020-2030

  • 市場概覽
  • 類風濕性關節炎藥物市場：按疾病類型分類（2020 年至 2030 年）
  • 類風濕性關節炎藥物市場：按藥物類型分類（2020 年至 2030 年）
  • 類風濕性關節炎藥物市場：按給藥方式分類（2020 年至 2030 年）
  • 類風濕性關節炎藥物市場：按銷售模式分類（2020-2030 年）
  • 類風濕性關節炎藥物市場：按最終用戶分類（2020-2030 年）
  • 按地區劃分的類風濕性關節炎藥物市場（2020 年至 2030 年）
    • 中東和非洲

第十五章公司簡介

  • AbbVie
  • Boehringer Ingelheim GmbH
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • UCB S.A.
  • Johnson & Johnson Services, Inc.
  • Amgen, Inc.
  • 其他
Product Code: 139421-12-22

The global market for rheumatoid arthritis treatments is expected to grow at a CAGR of 5% during the forecast period of 2022 to 2030. Rheumatology is the branch of internal medicine that deals with the diagnosis and treatment of rheumatic illnesses. Rheumatic disorders are characterized by joint, tendon, ligament, bone, and even organ inflammation. These conditions are commonly known as musculoskeletal illnesses and are characterized by significant pain, deformity, and morbidity. The procedure is typically very pricey. Multiple types of rheumatic diseases with varying symptoms are prevalent around the world in all age groups. The increasing incidence of rheumatoid arthritis is driving the expansion of the rheumatic treatment industry. Increased adoption of biopharmaceuticals and the availability of well-defined regulatory requirements in developed economies are among the key trends that are anticipated to drive market expansion. The development in awareness regarding the early detection and treatment of rheumatology disease symptoms and the increasing usage of disease-modifying anti-rheumatic medicines (DMARDs) for the treatment of the respective disease are the primary factors driving the growth of the rheumatology therapeutics market.

Increasing Innovations and Strong Drug Pipeline to Drive the Market

The increasing quantity of small molecules in the drug development pipeline, which is less expensive than biologics, has a positive impact on the rheumatic therapeutics market. In addition, the market for rheumatology therapeutics is positively impacted by an increase in the geriatric population, technological advancements in the pharmaceutical sector, rising investments in the healthcare industry, and an increase in the healthcare expenditures of the middle-income population. In addition, a rise in the pace of launches of novel biologics drugs, an increase in approvals, and a rise in the penetration of generic drugs will create lucrative prospects for market participants in the rheumatic therapeutics market during the forecast period. On the other side, high treatment costs and increased demand for biosimilar drugs are projected to hinder the growth of the rheumatology therapeutics market. During the forecast period, the market for rheumatology therapeutics is anticipated to witness challenges such as patent expiration of renowned medications used to treat rheumatic illnesses.

Increasing Prevalence of Rheumatic Illnesses

The Centers for Disease Control and Prevention have anticipated that by 2040, approximately 78 million US individuals (26% of the population) would be diagnosed with rheumatic disease. Osteoarthritis is the most prevalent kind, affecting around 26 million US adults2, followed by gout and fibromyalgia. Approximately 1.3 million US people have been diagnosed with rheumatoid arthritis, and between 200,000 and 300,000 have lupus4, not to add vasculitis and myositis, which primarily affect regions of the body other than the joints. However, the introduction of biosimilars represents a significant market constraint for rheumatic therapies. Increasing demand for biosimilars may impede the effectiveness of the conventional medicine routinely used to treat rheumatic illnesses. The expiration of patents on several medications used in the treatment of rheumatic illnesses also hinders the expansion of the market for rheumatology treatments.

Biopharma to Overtake Pharma Segment During the Forecast Period

Based on medicine type, the pharmaceuticals section, which includes analgesics, nonsteroidal anti-inflammatory drugs, and others, would account for significant growth during the forecast period from 2022 to 2030. Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for the symptomatic treatment of rheumatic disorders characterized by a variety of acute and chronic musculoskeletal pain. The primary impact of these medications is to reduce acute inflammation, hence lowering pain and enhancing general function. According to studies, in certain circumstances, smaller doses of NSAIDs are useful in reducing inflammation in RS. However, during the forecast period, the biopharma segment is expected to earn over 55% of the market share. Primarily, pharmaceuticals are utilized as the initial treatment for this condition. However, compared to biopharmaceuticals, their demand is expected to minimize due to the latter's greater therapeutic efficacy and disease-reversing properties. The division of biopharmaceuticals into biologics and biosimilars. For the treatment of RA, physicians prefer biologic medications over biosimilars, and biologics are expected to continue to dominate the market during the forecast period. Throughout the projected period, biologic pharmaceuticals are anticipated to account for the largest revenue share in developed nations. In developing nations, such as Brazil, Mexico, and South Africa, however, these treatments face significant competition from biosimilars and pharmaceutical generics due to the high cost of biologics. The segment's expansion is bolstered by increased availability, favorable outcomes, and affordable prices. During the forecast period, the introduction of new biosimilars is likely to cause a dramatic shift in prescription patterns.

Prescription Segment to Dominate During the Forecast Period

In recent years, there has been a dramatic increase in the number of people who prefer prescription drugs to over-the-counter drugs. The cause of the change is the increased awareness of novel illness-reversal treatment possibilities. Due to rising rheumatologist consultations, the prescription segment is expected to dominate the rheumatoid arthritis medications market over the forecast period. In order to avoid developing drug resistance, people with rheumatoid arthritis are encouraged to contact rheumatologists and adhere to their prescribed treatment. In addition, there are few over-the-counter treatments available. OTC medications contain a variety of active components, including acetaminophen and diclofenac.

Due to the approval of innovative treatments with fewer bad effects and rising awareness of disease remission prescription medicines for arthritis, the market share of these over-the-counter (OTC) drugs is anticipated to decline over the projection period. In addition, chronic use of over-the-counter medications for pain management may have major side effects, such as liver damage and addiction.

Online Sales Channel to Witness the Largest Growth During the Forecast Period

Regarding the sales channel, the online pharmacy market is projected to experience exponential growth. This can be attributed to the expanding e-commerce business and increased desire for online pharmaceutical sales in the wake of the COVID-19 outbreak. Increasing smartphone and internet penetration contribute to the expansion of the market sector. In addition, the availability of discounts and multiple products on several platforms would provide consumers with options, thereby strengthening the business environment.

North America Remains as the Global Leader

In 2021, North America accounted for more than 45.0% of the market for rheumatoid arthritis treatments. Patients' increased awareness of disease remission therapy, the increasing prevalence of rheumatoid arthritis, and the region's high public and private healthcare expenditures are driving the region's economic expansion. In addition, simple access to high-quality healthcare, advantageous reimbursement policies, a robust clinical pipeline, and the approval of innovative pharmaceuticals are anticipated to contribute to revenue growth in North America. The United States is at the forefront of growth in the region and a major contributor to global revenue. Rheumatoid arthritis affects approximately 860 out of every 100,000 people in the country. In price-sensitive nations such as Latin America and the Middle East and Africa, generic medications are more widely accepted than biologics developed by originator companies. During the projection period, the regional markets are expected to expand due to the rising need for innovative disease reversal treatments.

Asia-Pacific is projected to have the highest CAGR during the forecast period. Increasing urbanization is resulting in a growing patient population in the region. This, coupled with rising healthcare expenditures, is anticipated to push the APAC market. It is anticipated that favorable regulatory regulations for biosimilars will increase demand for therapeutics over the projected period.

Innovation and Strong Drug Pipeline to Enhance the Market Share

Due to the price-sensitive nature of the population in developing nations, only a few companies offer both branded and generic pharmaceuticals. To consolidate their position, businesses are focusing on developing unique chemical entities and inventive compounds. AbbVie, Boehringer Ingelheim GmbH, Novartis AG, Regeneron Pharmaceuticals, Inc., Pfizer, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., UCB S.A., Johnson & Johnson Services, Inc., and Amgen, Inc. are notable market participants. The introduction of innovative biologics and a robust clinical pipeline are expected to increase market competitiveness. Due to the low entry barriers in the RA medicines industry, the generic pharmaceuticals segment is set for new players.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Rheumatology Arthritis Therapeutics market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Rheumatology Arthritis Therapeutics market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Disease Type

Osteoarthritis

Ankylosing spondylitis

Rheumatoid arthritis

Gout

Psoriatic arthritis

Reactive arthritis

Fibromyalgia

Scleroderma

Others

Drug Type

Pharmaceuticals

NSAIDs

Analgesics

DMARDs

Glucocorticoids

Biopharmaceuticals

Biologics

TNF-α antagonists

T-cell inhibitors

CD20 antigen

JAK inhibitors

anti-IL6 biologics

Biosimilars

CD20 antigen

TNF-α antagonists

Method of Administration

Topical

Oral

Parenteral

Mode of Sale

Prescription drugs

Over-the-counter drugs

End User

Hospitals

Medical clinics

Online channel

Retail Channel

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of Covid-19 Segment (2020-2021; US$ Million )

Pre Covid-19 situation

Post Covid-19 situation

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Rheumatology Arthritis Therapeutics market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Rheumatology Arthritis Therapeutics market?
  • Which is the largest regional market for Rheumatology Arthritis Therapeutics market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Rheumatology Arthritis Therapeutics market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Rheumatology Arthritis Therapeutics market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Rheumatology Arthritis Therapeutics Market
  • 2.2. Global Rheumatology Arthritis Therapeutics Market, By Disease Type, 2021 (US$ Million)
  • 2.3. Global Rheumatology Arthritis Therapeutics Market, By Drug Type, 2021 (US$ Million)
  • 2.4. Global Rheumatology Arthritis Therapeutics Market, By Method of Administration, 2021 (US$ Million)
  • 2.5. Global Rheumatology Arthritis Therapeutics Market, By Mode of Sale, 2021 (US$ Million)
  • 2.6. Global Rheumatology Arthritis Therapeutics Market, By End User, 2021 (US$ Million)
  • 2.7. Global Rheumatology Arthritis Therapeutics Market, By Geography, 2021 (US$ Million)
  • 2.8. Attractive Investment Proposition by Geography, 2021

3. Rheumatology Arthritis Therapeutics Market: Competitive Analysis

  • 3.1. Market Positioning of Key Rheumatology Arthritis Therapeutics Market Vendors
  • 3.2. Strategies Adopted by Rheumatology Arthritis Therapeutics Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2021 Versus 2030

4. Rheumatology Arthritis Therapeutics Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Rheumatology Arthritis Therapeutics Market Value, 2020 - 2030, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Rheumatology Arthritis Therapeutics Market: By Disease Type, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. Osteoarthritis
    • 5.3.2. Ankylosing spondylitis
    • 5.3.3. Rheumatoid arthritis
    • 5.3.4. Gout
    • 5.3.5. Psoriatic arthritis
    • 5.3.6. Reactive arthritis
    • 5.3.7. Fibromyalgia
    • 5.3.8. Scleroderma
    • 5.3.9. Others

6. Rheumatology Arthritis Therapeutics Market: By Drug Type, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 6.3. Market Segmentation
    • 6.3.1. Pharmaceuticals
      • 6.3.1.1. NSAIDs
      • 6.3.1.2. Analgesics
      • 6.3.1.3. DMARDs
      • 6.3.1.4. Glucocorticoids
    • 6.3.2. Biopharmaceuticals
      • 6.3.2.1. Biologics
      • 6.3.2.2. TNF-α antagonists
      • 6.3.2.3. T-cell inhibitors
      • 6.3.2.4. CD20 antigen
      • 6.3.2.5. JAK inhibitors
      • 6.3.2.6. anti-IL6 biologics
    • 6.3.3. Biosimilars
      • 6.3.3.1. CD20 antigen
      • 6.3.3.2. TNF-α antagonists

7. Rheumatology Arthritis Therapeutics Market: By Method of Administration, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 7.3. Market Segmentation
    • 7.3.1. Topical
    • 7.3.2. Oral
    • 7.3.3. Parenteral

8. Rheumatology Arthritis Therapeutics Market: By Mode of Sale, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 8.3. Market Segmentation
    • 8.3.1. Prescription drugs
    • 8.3.2. Over-the-counter drugs

9. Rheumatology Arthritis Therapeutics Market: By End User, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 9.3. Market Segmentation
    • 9.3.1. Hospitals
    • 9.3.2. Medical clinics
    • 9.3.3. Online channel
    • 9.3.4. Retail Channel

10. North America Rheumatology Arthritis Therapeutics Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Rheumatology Arthritis Therapeutics Market: By Disease Type, 2020-2030, USD (Million)
  • 10.3. Rheumatology Arthritis Therapeutics Market: By Drug Type, 2020-2030, USD (Million)
  • 10.4. Rheumatology Arthritis Therapeutics Market: By Method of Administration, 2020-2030, USD (Million)
  • 10.5. Rheumatology Arthritis Therapeutics Market: By Mode of Sale, 2020-2030, USD (Million)
  • 10.6. Rheumatology Arthritis Therapeutics Market: By End User, 2020-2030, USD (Million)
  • 10.7.Rheumatology Arthritis Therapeutics Market: By Region, 2020-2030, USD (Million)
    • 10.7.1.North America
      • 10.7.1.1. U.S.
        • 10.7.1.1.1. Rheumatology Arthritis Therapeutics Market: By Disease Type, 2020-2030, USD (Million)
        • 10.7.1.1.1. Rheumatology Arthritis Therapeutics Market: By Drug Type, 2020-2030, USD (Million)
        • 10.7.1.1.1. Rheumatology Arthritis Therapeutics Market: By Method of Administration, 2020-2030, USD (Million)
        • 10.7.1.1.1. Rheumatology Arthritis Therapeutics Market: By Mode of Sale, 2020-2030, USD (Million)
        • 10.7.1.1.1. Rheumatology Arthritis Therapeutics Market: By End User, 2020-2030, USD (Million)
      • 10.7.1.2. Canada
        • 10.7.1.2.1. Rheumatology Arthritis Therapeutics Market: By Disease Type, 2020-2030, USD (Million)
        • 10.7.1.2.1. Rheumatology Arthritis Therapeutics Market: By Drug Type, 2020-2030, USD (Million)
        • 10.7.1.2.1. Rheumatology Arthritis Therapeutics Market: By Method of Administration, 2020-2030, USD (Million)
        • 10.7.1.2.1. Rheumatology Arthritis Therapeutics Market: By Mode of Sale, 2020-2030, USD (Million)
        • 10.7.1.2.1. Rheumatology Arthritis Therapeutics Market: By End User, 2020-2030, USD (Million)
      • 10.7.1.3. Rest of North America
        • 10.7.1.3.1. Rheumatology Arthritis Therapeutics Market: By Disease Type, 2020-2030, USD (Million)
        • 10.7.1.3.1. Rheumatology Arthritis Therapeutics Market: By Drug Type, 2020-2030, USD (Million)
        • 10.7.1.3.1. Rheumatology Arthritis Therapeutics Market: By Method of Administration, 2020-2030, USD (Million)
        • 10.7.1.3.1. Rheumatology Arthritis Therapeutics Market: By Mode of Sale, 2020-2030, USD (Million)
        • 10.7.1.3.1. Rheumatology Arthritis Therapeutics Market: By End User, 2020-2030, USD (Million)

11. UK and European Union Rheumatology Arthritis Therapeutics Market, 2020-2030, USD (Million)

  • 11.1. Market Overview
  • 11.2. Rheumatology Arthritis Therapeutics Market: By Disease Type, 2020-2030, USD (Million)
  • 11.3. Rheumatology Arthritis Therapeutics Market: By Drug Type, 2020-2030, USD (Million)
  • 11.4. Rheumatology Arthritis Therapeutics Market: By Method of Administration, 2020-2030, USD (Million)
  • 11.5. Rheumatology Arthritis Therapeutics Market: By Mode of Sale, 2020-2030, USD (Million)
  • 11.6. Rheumatology Arthritis Therapeutics Market: By End User, 2020-2030, USD (Million)
  • 11.7.Rheumatology Arthritis Therapeutics Market: By Region, 2020-2030, USD (Million)
    • 11.7.1.UK and European Union
      • 11.7.1.1. UK
        • 11.7.1.1.1. Rheumatology Arthritis Therapeutics Market: By Disease Type, 2020-2030, USD (Million)
        • 11.7.1.1.1. Rheumatology Arthritis Therapeutics Market: By Drug Type, 2020-2030, USD (Million)
        • 11.7.1.1.1. Rheumatology Arthritis Therapeutics Market: By Method of Administration, 2020-2030, USD (Million)
        • 11.7.1.1.1. Rheumatology Arthritis Therapeutics Market: By Mode of Sale, 2020-2030, USD (Million)
        • 11.7.1.1.1. Rheumatology Arthritis Therapeutics Market: By End User, 2020-2030, USD (Million)
      • 11.7.1.2. Germany
        • 11.7.1.2.1. Rheumatology Arthritis Therapeutics Market: By Disease Type, 2020-2030, USD (Million)
        • 11.7.1.2.1. Rheumatology Arthritis Therapeutics Market: By Drug Type, 2020-2030, USD (Million)
        • 11.7.1.2.1. Rheumatology Arthritis Therapeutics Market: By Method of Administration, 2020-2030, USD (Million)
        • 11.7.1.2.1. Rheumatology Arthritis Therapeutics Market: By Mode of Sale, 2020-2030, USD (Million)
        • 11.7.1.2.1. Rheumatology Arthritis Therapeutics Market: By End User, 2020-2030, USD (Million)
      • 11.7.1.3. Spain
        • 11.7.1.3.1. Rheumatology Arthritis Therapeutics Market: By Disease Type, 2020-2030, USD (Million)
        • 11.7.1.3.1. Rheumatology Arthritis Therapeutics Market: By Drug Type, 2020-2030, USD (Million)
        • 11.7.1.3.1. Rheumatology Arthritis Therapeutics Market: By Method of Administration, 2020-2030, USD (Million)
        • 11.7.1.3.1. Rheumatology Arthritis Therapeutics Market: By Mode of Sale, 2020-2030, USD (Million)
        • 11.7.1.3.1. Rheumatology Arthritis Therapeutics Market: By End User, 2020-2030, USD (Million)
      • 11.7.1.4. Italy
        • 11.7.1.4.1. Rheumatology Arthritis Therapeutics Market: By Disease Type, 2020-2030, USD (Million)
        • 11.7.1.4.1. Rheumatology Arthritis Therapeutics Market: By Drug Type, 2020-2030, USD (Million)
        • 11.7.1.4.1. Rheumatology Arthritis Therapeutics Market: By Method of Administration, 2020-2030, USD (Million)
        • 11.7.1.4.1. Rheumatology Arthritis Therapeutics Market: By Mode of Sale, 2020-2030, USD (Million)
        • 11.7.1.4.1. Rheumatology Arthritis Therapeutics Market: By End User, 2020-2030, USD (Million)
      • 11.7.1.5. France
        • 11.7.1.5.1. Rheumatology Arthritis Therapeutics Market: By Disease Type, 2020-2030, USD (Million)
        • 11.7.1.5.1. Rheumatology Arthritis Therapeutics Market: By Drug Type, 2020-2030, USD (Million)
        • 11.7.1.5.1. Rheumatology Arthritis Therapeutics Market: By Method of Administration, 2020-2030, USD (Million)
        • 11.7.1.5.1. Rheumatology Arthritis Therapeutics Market: By Mode of Sale, 2020-2030, USD (Million)
        • 11.7.1.5.1. Rheumatology Arthritis Therapeutics Market: By End User, 2020-2030, USD (Million)
      • 11.7.1.6. Rest of Europe
        • 11.7.1.6.1. Rheumatology Arthritis Therapeutics Market: By Disease Type, 2020-2030, USD (Million)
        • 11.7.1.6.1. Rheumatology Arthritis Therapeutics Market: By Drug Type, 2020-2030, USD (Million)
        • 11.7.1.6.1. Rheumatology Arthritis Therapeutics Market: By Method of Administration, 2020-2030, USD (Million)
        • 11.7.1.6.1. Rheumatology Arthritis Therapeutics Market: By Mode of Sale, 2020-2030, USD (Million)
        • 11.7.1.6.1. Rheumatology Arthritis Therapeutics Market: By End User, 2020-2030, USD (Million)

12. Asia Pacific Rheumatology Arthritis Therapeutics Market, 2020-2030, USD (Million)

  • 12.1. Market Overview
  • 12.2. Rheumatology Arthritis Therapeutics Market: By Disease Type, 2020-2030, USD (Million)
  • 12.3. Rheumatology Arthritis Therapeutics Market: By Drug Type, 2020-2030, USD (Million)
  • 12.4. Rheumatology Arthritis Therapeutics Market: By Method of Administration, 2020-2030, USD (Million)
  • 12.5. Rheumatology Arthritis Therapeutics Market: By Mode of Sale, 2020-2030, USD (Million)
  • 12.6. Rheumatology Arthritis Therapeutics Market: By End User, 2020-2030, USD (Million)
  • 12.7.Rheumatology Arthritis Therapeutics Market: By Region, 2020-2030, USD (Million)
    • 12.7.1.Asia Pacific
      • 12.7.1.1. China
        • 12.7.1.1.1. Rheumatology Arthritis Therapeutics Market: By Disease Type, 2020-2030, USD (Million)
        • 12.7.1.1.1. Rheumatology Arthritis Therapeutics Market: By Drug Type, 2020-2030, USD (Million)
        • 12.7.1.1.1. Rheumatology Arthritis Therapeutics Market: By Method of Administration, 2020-2030, USD (Million)
        • 12.7.1.1.1. Rheumatology Arthritis Therapeutics Market: By Mode of Sale, 2020-2030, USD (Million)
        • 12.7.1.1.1. Rheumatology Arthritis Therapeutics Market: By End User, 2020-2030, USD (Million)
      • 12.7.1.2. Japan
        • 12.7.1.2.1. Rheumatology Arthritis Therapeutics Market: By Disease Type, 2020-2030, USD (Million)
        • 12.7.1.2.1. Rheumatology Arthritis Therapeutics Market: By Drug Type, 2020-2030, USD (Million)
        • 12.7.1.2.1. Rheumatology Arthritis Therapeutics Market: By Method of Administration, 2020-2030, USD (Million)
        • 12.7.1.2.1. Rheumatology Arthritis Therapeutics Market: By Mode of Sale, 2020-2030, USD (Million)
        • 12.7.1.2.1. Rheumatology Arthritis Therapeutics Market: By End User, 2020-2030, USD (Million)
      • 12.7.1.3. India
        • 12.7.1.3.1. Rheumatology Arthritis Therapeutics Market: By Disease Type, 2020-2030, USD (Million)
        • 12.7.1.3.1. Rheumatology Arthritis Therapeutics Market: By Drug Type, 2020-2030, USD (Million)
        • 12.7.1.3.1. Rheumatology Arthritis Therapeutics Market: By Method of Administration, 2020-2030, USD (Million)
        • 12.7.1.3.1. Rheumatology Arthritis Therapeutics Market: By Mode of Sale, 2020-2030, USD (Million)
        • 12.7.1.3.1. Rheumatology Arthritis Therapeutics Market: By End User, 2020-2030, USD (Million)
      • 12.7.1.4. Australia
        • 12.7.1.4.1. Rheumatology Arthritis Therapeutics Market: By Disease Type, 2020-2030, USD (Million)
        • 12.7.1.4.1. Rheumatology Arthritis Therapeutics Market: By Drug Type, 2020-2030, USD (Million)
        • 12.7.1.4.1. Rheumatology Arthritis Therapeutics Market: By Method of Administration, 2020-2030, USD (Million)
        • 12.7.1.4.1. Rheumatology Arthritis Therapeutics Market: By Mode of Sale, 2020-2030, USD (Million)
        • 12.7.1.4.1. Rheumatology Arthritis Therapeutics Market: By End User, 2020-2030, USD (Million)
      • 12.7.1.5. South Korea
        • 12.7.1.5.1. Rheumatology Arthritis Therapeutics Market: By Disease Type, 2020-2030, USD (Million)
        • 12.7.1.5.1. Rheumatology Arthritis Therapeutics Market: By Drug Type, 2020-2030, USD (Million)
        • 12.7.1.5.1. Rheumatology Arthritis Therapeutics Market: By Method of Administration, 2020-2030, USD (Million)
        • 12.7.1.5.1. Rheumatology Arthritis Therapeutics Market: By Mode of Sale, 2020-2030, USD (Million)
        • 12.7.1.5.1. Rheumatology Arthritis Therapeutics Market: By End User, 2020-2030, USD (Million)
      • 12.7.1.6. Rest of Asia Pacific
        • 12.7.1.6.1. Rheumatology Arthritis Therapeutics Market: By Disease Type, 2020-2030, USD (Million)
        • 12.7.1.6.1. Rheumatology Arthritis Therapeutics Market: By Drug Type, 2020-2030, USD (Million)
        • 12.7.1.6.1. Rheumatology Arthritis Therapeutics Market: By Method of Administration, 2020-2030, USD (Million)
        • 12.7.1.6.1. Rheumatology Arthritis Therapeutics Market: By Mode of Sale, 2020-2030, USD (Million)
        • 12.7.1.6.1. Rheumatology Arthritis Therapeutics Market: By End User, 2020-2030, USD (Million)

13. Latin America Rheumatology Arthritis Therapeutics Market, 2020-2030, USD (Million)

  • 13.1. Market Overview
  • 13.2. Rheumatology Arthritis Therapeutics Market: By Disease Type, 2020-2030, USD (Million)
  • 13.3. Rheumatology Arthritis Therapeutics Market: By Drug Type, 2020-2030, USD (Million)
  • 13.4. Rheumatology Arthritis Therapeutics Market: By Method of Administration, 2020-2030, USD (Million)
  • 13.5. Rheumatology Arthritis Therapeutics Market: By Mode of Sale, 2020-2030, USD (Million)
  • 13.6. Rheumatology Arthritis Therapeutics Market: By End User, 2020-2030, USD (Million)
  • 13.7.Rheumatology Arthritis Therapeutics Market: By Region, 2020-2030, USD (Million)
    • 13.7.1.Latin America
      • 13.7.1.1. Brazil
        • 13.7.1.1.1. Rheumatology Arthritis Therapeutics Market: By Disease Type, 2020-2030, USD (Million)
        • 13.7.1.1.1. Rheumatology Arthritis Therapeutics Market: By Drug Type, 2020-2030, USD (Million)
        • 13.7.1.1.1. Rheumatology Arthritis Therapeutics Market: By Method of Administration, 2020-2030, USD (Million)
        • 13.7.1.1.1. Rheumatology Arthritis Therapeutics Market: By Mode of Sale, 2020-2030, USD (Million)
        • 13.7.1.1.1. Rheumatology Arthritis Therapeutics Market: By End User, 2020-2030, USD (Million)
      • 13.7.1.2. Mexico
        • 13.7.1.2.1. Rheumatology Arthritis Therapeutics Market: By Disease Type, 2020-2030, USD (Million)
        • 13.7.1.2.1. Rheumatology Arthritis Therapeutics Market: By Drug Type, 2020-2030, USD (Million)
        • 13.7.1.2.1. Rheumatology Arthritis Therapeutics Market: By Method of Administration, 2020-2030, USD (Million)
        • 13.7.1.2.1. Rheumatology Arthritis Therapeutics Market: By Mode of Sale, 2020-2030, USD (Million)
        • 13.7.1.2.1. Rheumatology Arthritis Therapeutics Market: By End User, 2020-2030, USD (Million)
      • 13.7.1.3. Rest of Latin America
        • 13.7.1.3.1. Rheumatology Arthritis Therapeutics Market: By Disease Type, 2020-2030, USD (Million)
        • 13.7.1.3.1. Rheumatology Arthritis Therapeutics Market: By Drug Type, 2020-2030, USD (Million)
        • 13.7.1.3.1. Rheumatology Arthritis Therapeutics Market: By Method of Administration, 2020-2030, USD (Million)
        • 13.7.1.3.1. Rheumatology Arthritis Therapeutics Market: By Mode of Sale, 2020-2030, USD (Million)
        • 13.7.1.3.1. Rheumatology Arthritis Therapeutics Market: By End User, 2020-2030, USD (Million)

14. Middle East and Africa Rheumatology Arthritis Therapeutics Market, 2020-2030, USD (Million)

  • 14.1. Market Overview
  • 14.2. Rheumatology Arthritis Therapeutics Market: By Disease Type, 2020-2030, USD (Million)
  • 14.3. Rheumatology Arthritis Therapeutics Market: By Drug Type, 2020-2030, USD (Million)
  • 14.4. Rheumatology Arthritis Therapeutics Market: By Method of Administration, 2020-2030, USD (Million)
  • 14.5. Rheumatology Arthritis Therapeutics Market: By Mode of Sale, 2020-2030, USD (Million)
  • 14.6. Rheumatology Arthritis Therapeutics Market: By End User, 2020-2030, USD (Million)
  • 14.7.Rheumatology Arthritis Therapeutics Market: By Region, 2020-2030, USD (Million)
    • 14.7.1.Middle East and Africa
      • 14.7.1.1. GCC
        • 14.7.1.1.1. Rheumatology Arthritis Therapeutics Market: By Disease Type, 2020-2030, USD (Million)
        • 14.7.1.1.1. Rheumatology Arthritis Therapeutics Market: By Drug Type, 2020-2030, USD (Million)
        • 14.7.1.1.1. Rheumatology Arthritis Therapeutics Market: By Method of Administration, 2020-2030, USD (Million)
        • 14.7.1.1.1. Rheumatology Arthritis Therapeutics Market: By Mode of Sale, 2020-2030, USD (Million)
        • 14.7.1.1.1. Rheumatology Arthritis Therapeutics Market: By End User, 2020-2030, USD (Million)
      • 14.7.1.2. Africa
        • 14.7.1.2.1. Rheumatology Arthritis Therapeutics Market: By Disease Type, 2020-2030, USD (Million)
        • 14.7.1.2.1. Rheumatology Arthritis Therapeutics Market: By Drug Type, 2020-2030, USD (Million)
        • 14.7.1.2.1. Rheumatology Arthritis Therapeutics Market: By Method of Administration, 2020-2030, USD (Million)
        • 14.7.1.2.1. Rheumatology Arthritis Therapeutics Market: By Mode of Sale, 2020-2030, USD (Million)
        • 14.7.1.2.1. Rheumatology Arthritis Therapeutics Market: By End User, 2020-2030, USD (Million)
      • 14.7.1.3. Rest of Middle East and Africa
        • 14.7.1.3.1. Rheumatology Arthritis Therapeutics Market: By Disease Type, 2020-2030, USD (Million)
        • 14.7.1.3.1. Rheumatology Arthritis Therapeutics Market: By Drug Type, 2020-2030, USD (Million)
        • 14.7.1.3.1. Rheumatology Arthritis Therapeutics Market: By Method of Administration, 2020-2030, USD (Million)
        • 14.7.1.3.1. Rheumatology Arthritis Therapeutics Market: By Mode of Sale, 2020-2030, USD (Million)
        • 14.7.1.3.1. Rheumatology Arthritis Therapeutics Market: By End User, 2020-2030, USD (Million)

15. Company Profile

  • 15.1. AbbVie
    • 15.1.1. Company Overview
    • 15.1.2. Financial Performance
    • 15.1.3. Product Portfolio
    • 15.1.4. Strategic Initiatives
  • 15.2. Boehringer Ingelheim GmbH
    • 15.2.1. Company Overview
    • 15.2.2. Financial Performance
    • 15.2.3. Product Portfolio
    • 15.2.4. Strategic Initiatives
  • 15.3. Novartis AG
    • 15.3.1. Company Overview
    • 15.3.2. Financial Performance
    • 15.3.3. Product Portfolio
    • 15.3.4. Strategic Initiatives
  • 15.4. Regeneron Pharmaceuticals, Inc.
    • 15.4.1. Company Overview
    • 15.4.2. Financial Performance
    • 15.4.3. Product Portfolio
    • 15.4.4. Strategic Initiatives
  • 15.5. Pfizer, Inc.
    • 15.5.1. Company Overview
    • 15.5.2. Financial Performance
    • 15.5.3. Product Portfolio
    • 15.5.4. Strategic Initiatives
  • 15.6. Bristol-Myers Squibb Company
    • 15.6.1. Company Overview
    • 15.6.2. Financial Performance
    • 15.6.3. Product Portfolio
    • 15.6.4. Strategic Initiatives
  • 15.7. F. Hoffmann-La Roche Ltd.
    • 15.7.1. Company Overview
    • 15.7.2. Financial Performance
    • 15.7.3. Product Portfolio
    • 15.7.4. Strategic Initiatives
  • 15.8. UCB S.A.
    • 15.8.1. Company Overview
    • 15.8.2. Financial Performance
    • 15.8.3. Product Portfolio
    • 15.8.4. Strategic Initiatives
  • 15.9. Johnson & Johnson Services, Inc.
    • 15.9.1. Company Overview
    • 15.9.2. Financial Performance
    • 15.9.3. Product Portfolio
    • 15.9.4. Strategic Initiatives
  • 15.10. Amgen, Inc.
    • 15.10.1. Company Overview
    • 15.10.2. Financial Performance
    • 15.10.3. Product Portfolio
    • 15.10.4. Strategic Initiatives
  • 15.11. Others
    • 15.11.1. Company Overview
    • 15.11.2. Financial Performance
    • 15.11.3. Product Portfolio
    • 15.11.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Rheumatology Arthritis Therapeutics Market By Disease Type, 2020-2030, USD (Million)
  • TABLE 2 Global Rheumatology Arthritis Therapeutics Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 3 Global Rheumatology Arthritis Therapeutics Market By Pharmaceuticals, 2020-2030, USD (Million)
  • TABLE 4 Global Rheumatology Arthritis Therapeutics Market By Biopharmaceuticals, 2020-2030, USD (Million)
  • TABLE 5 Global Rheumatology Arthritis Therapeutics Market By Biosimilars, 2020-2030, USD (Million)
  • TABLE 6 Global Rheumatology Arthritis Therapeutics Market By Method of Administration, 2020-2030, USD (Million)
  • TABLE 7 Global Rheumatology Arthritis Therapeutics Market By Mode of Sale, 2020-2030, USD (Million)
  • TABLE 8 Global Rheumatology Arthritis Therapeutics Market By End User, 2020-2030, USD (Million)
  • TABLE 9 North America Rheumatology Arthritis Therapeutics Market By Disease Type, 2020-2030, USD (Million)
  • TABLE 10 North America Rheumatology Arthritis Therapeutics Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 11 North America Rheumatology Arthritis Therapeutics Market By Pharmaceuticals, 2020-2030, USD (Million)
  • TABLE 12 North America Rheumatology Arthritis Therapeutics Market By Biopharmaceuticals, 2020-2030, USD (Million)
  • TABLE 13 North America Rheumatology Arthritis Therapeutics Market By Biosimilars, 2020-2030, USD (Million)
  • TABLE 14 North America Rheumatology Arthritis Therapeutics Market By Method of Administration, 2020-2030, USD (Million)
  • TABLE 15 North America Rheumatology Arthritis Therapeutics Market By Mode of Sale, 2020-2030, USD (Million)
  • TABLE 16 North America Rheumatology Arthritis Therapeutics Market By End User, 2020-2030, USD (Million)
  • TABLE 17 U.S. Rheumatology Arthritis Therapeutics Market By Disease Type, 2020-2030, USD (Million)
  • TABLE 18 U.S. Rheumatology Arthritis Therapeutics Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 19 U.S. Rheumatology Arthritis Therapeutics Market By Pharmaceuticals, 2020-2030, USD (Million)
  • TABLE 20 U.S. Rheumatology Arthritis Therapeutics Market By Biopharmaceuticals, 2020-2030, USD (Million)
  • TABLE 21 U.S. Rheumatology Arthritis Therapeutics Market By Biosimilars, 2020-2030, USD (Million)
  • TABLE 22 U.S. Rheumatology Arthritis Therapeutics Market By Method of Administration, 2020-2030, USD (Million)
  • TABLE 23 U.S. Rheumatology Arthritis Therapeutics Market By Mode of Sale, 2020-2030, USD (Million)
  • TABLE 24 U.S. Rheumatology Arthritis Therapeutics Market By End User, 2020-2030, USD (Million)
  • TABLE 25 Canada Rheumatology Arthritis Therapeutics Market By Disease Type, 2020-2030, USD (Million)
  • TABLE 26 Canada Rheumatology Arthritis Therapeutics Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 27 Canada Rheumatology Arthritis Therapeutics Market By Pharmaceuticals, 2020-2030, USD (Million)
  • TABLE 28 Canada Rheumatology Arthritis Therapeutics Market By Biopharmaceuticals, 2020-2030, USD (Million)
  • TABLE 29 Canada Rheumatology Arthritis Therapeutics Market By Biosimilars, 2020-2030, USD (Million)
  • TABLE 30 Canada Rheumatology Arthritis Therapeutics Market By Method of Administration, 2020-2030, USD (Million)
  • TABLE 31 Canada Rheumatology Arthritis Therapeutics Market By Mode of Sale, 2020-2030, USD (Million)
  • TABLE 32 Canada Rheumatology Arthritis Therapeutics Market By End User, 2020-2030, USD (Million)
  • TABLE 33 Rest of North America Rheumatology Arthritis Therapeutics Market By Disease Type, 2020-2030, USD (Million)
  • TABLE 34 Rest of North America Rheumatology Arthritis Therapeutics Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 35 Rest of North America Rheumatology Arthritis Therapeutics Market By Pharmaceuticals, 2020-2030, USD (Million)
  • TABLE 36 Rest of North America Rheumatology Arthritis Therapeutics Market By Biopharmaceuticals, 2020-2030, USD (Million)
  • TABLE 37 Rest of North America Rheumatology Arthritis Therapeutics Market By Biosimilars, 2020-2030, USD (Million)
  • TABLE 38 Rest of North America Rheumatology Arthritis Therapeutics Market By Method of Administration, 2020-2030, USD (Million)
  • TABLE 39 Rest of North America Rheumatology Arthritis Therapeutics Market By Mode of Sale, 2020-2030, USD (Million)
  • TABLE 40 Rest of North America Rheumatology Arthritis Therapeutics Market By End User, 2020-2030, USD (Million)
  • TABLE 41 UK and European Union Rheumatology Arthritis Therapeutics Market By Disease Type, 2020-2030, USD (Million)
  • TABLE 42 UK and European Union Rheumatology Arthritis Therapeutics Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 43 UK and European Union Rheumatology Arthritis Therapeutics Market By Pharmaceuticals, 2020-2030, USD (Million)
  • TABLE 44 UK and European Union Rheumatology Arthritis Therapeutics Market By Biopharmaceuticals, 2020-2030, USD (Million)
  • TABLE 45 UK and European Union Rheumatology Arthritis Therapeutics Market By Biosimilars, 2020-2030, USD (Million)
  • TABLE 46 UK and European Union Rheumatology Arthritis Therapeutics Market By Method of Administration, 2020-2030, USD (Million)
  • TABLE 47 UK and European Union Rheumatology Arthritis Therapeutics Market By Mode of Sale, 2020-2030, USD (Million)
  • TABLE 48 UK and European Union Rheumatology Arthritis Therapeutics Market By End User, 2020-2030, USD (Million)
  • TABLE 49 UK Rheumatology Arthritis Therapeutics Market By Disease Type, 2020-2030, USD (Million)
  • TABLE 50 UK Rheumatology Arthritis Therapeutics Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 51 UK Rheumatology Arthritis Therapeutics Market By Pharmaceuticals, 2020-2030, USD (Million)
  • TABLE 52 UK Rheumatology Arthritis Therapeutics Market By Biopharmaceuticals, 2020-2030, USD (Million)
  • TABLE 53 UK Rheumatology Arthritis Therapeutics Market By Biosimilars, 2020-2030, USD (Million)
  • TABLE 54 UK Rheumatology Arthritis Therapeutics Market By Method of Administration, 2020-2030, USD (Million)
  • TABLE 55 UK Rheumatology Arthritis Therapeutics Market By Mode of Sale, 2020-2030, USD (Million)
  • TABLE 56 UK Rheumatology Arthritis Therapeutics Market By End User, 2020-2030, USD (Million)
  • TABLE 57 Germany Rheumatology Arthritis Therapeutics Market By Disease Type, 2020-2030, USD (Million)
  • TABLE 58 Germany Rheumatology Arthritis Therapeutics Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 59 Germany Rheumatology Arthritis Therapeutics Market By Pharmaceuticals, 2020-2030, USD (Million)
  • TABLE 60 Germany Rheumatology Arthritis Therapeutics Market By Biopharmaceuticals, 2020-2030, USD (Million)
  • TABLE 61 Germany Rheumatology Arthritis Therapeutics Market By Biosimilars, 2020-2030, USD (Million)
  • TABLE 62 Germany Rheumatology Arthritis Therapeutics Market By Method of Administration, 2020-2030, USD (Million)
  • TABLE 63 Germany Rheumatology Arthritis Therapeutics Market By Mode of Sale, 2020-2030, USD (Million)
  • TABLE 64 Germany Rheumatology Arthritis Therapeutics Market By End User, 2020-2030, USD (Million)
  • TABLE 65 Spain Rheumatology Arthritis Therapeutics Market By Disease Type, 2020-2030, USD (Million)
  • TABLE 66 Spain Rheumatology Arthritis Therapeutics Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 67 Spain Rheumatology Arthritis Therapeutics Market By Pharmaceuticals, 2020-2030, USD (Million)
  • TABLE 68 Spain Rheumatology Arthritis Therapeutics Market By Biopharmaceuticals, 2020-2030, USD (Million)
  • TABLE 69 Spain Rheumatology Arthritis Therapeutics Market By Biosimilars, 2020-2030, USD (Million)
  • TABLE 70 Spain Rheumatology Arthritis Therapeutics Market By Method of Administration, 2020-2030, USD (Million)
  • TABLE 71 Spain Rheumatology Arthritis Therapeutics Market By Mode of Sale, 2020-2030, USD (Million)
  • TABLE 72 Spain Rheumatology Arthritis Therapeutics Market By End User, 2020-2030, USD (Million)
  • TABLE 73 Italy Rheumatology Arthritis Therapeutics Market By Disease Type, 2020-2030, USD (Million)
  • TABLE 74 Italy Rheumatology Arthritis Therapeutics Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 75 Italy Rheumatology Arthritis Therapeutics Market By Pharmaceuticals, 2020-2030, USD (Million)
  • TABLE 76 Italy Rheumatology Arthritis Therapeutics Market By Biopharmaceuticals, 2020-2030, USD (Million)
  • TABLE 77 Italy Rheumatology Arthritis Therapeutics Market By Biosimilars, 2020-2030, USD (Million)
  • TABLE 78 Italy Rheumatology Arthritis Therapeutics Market By Method of Administration, 2020-2030, USD (Million)
  • TABLE 79 Italy Rheumatology Arthritis Therapeutics Market By Mode of Sale, 2020-2030, USD (Million)
  • TABLE 80 Italy Rheumatology Arthritis Therapeutics Market By End User, 2020-2030, USD (Million)
  • TABLE 81 France Rheumatology Arthritis Therapeutics Market By Disease Type, 2020-2030, USD (Million)
  • TABLE 82 France Rheumatology Arthritis Therapeutics Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 83 France Rheumatology Arthritis Therapeutics Market By Pharmaceuticals, 2020-2030, USD (Million)
  • TABLE 84 France Rheumatology Arthritis Therapeutics Market By Biopharmaceuticals, 2020-2030, USD (Million)
  • TABLE 85 France Rheumatology Arthritis Therapeutics Market By Biosimilars, 2020-2030, USD (Million)
  • TABLE 86 France Rheumatology Arthritis Therapeutics Market By Method of Administration, 2020-2030, USD (Million)
  • TABLE 87 France Rheumatology Arthritis Therapeutics Market By Mode of Sale, 2020-2030, USD (Million)
  • TABLE 88 France Rheumatology Arthritis Therapeutics Market By End User, 2020-2030, USD (Million)
  • TABLE 89 Rest of Europe Rheumatology Arthritis Therapeutics Market By Disease Type, 2020-2030, USD (Million)
  • TABLE 90 Rest of Europe Rheumatology Arthritis Therapeutics Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 91 Rest of Europe Rheumatology Arthritis Therapeutics Market By Pharmaceuticals, 2020-2030, USD (Million)
  • TABLE 92 Rest of Europe Rheumatology Arthritis Therapeutics Market By Biopharmaceuticals, 2020-2030, USD (Million)
  • TABLE 93 Rest of Europe Rheumatology Arthritis Therapeutics Market By Biosimilars, 2020-2030, USD (Million)
  • TABLE 94 Rest of Europe Rheumatology Arthritis Therapeutics Market By Method of Administration, 2020-2030, USD (Million)
  • TABLE 95 Rest of Europe Rheumatology Arthritis Therapeutics Market By Mode of Sale, 2020-2030, USD (Million)
  • TABLE 96 Rest of Europe Rheumatology Arthritis Therapeutics Market By End User, 2020-2030, USD (Million)
  • TABLE 97 Asia Rheumatology Arthritis Therapeutics Market By Disease Type, 2020-2030, USD (Million)
  • TABLE 98 Asia Rheumatology Arthritis Therapeutics Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 99 Asia Rheumatology Arthritis Therapeutics Market By Pharmaceuticals, 2020-2030, USD (Million)
  • TABLE 100 Asia Rheumatology Arthritis Therapeutics Market By Biopharmaceuticals, 2020-2030, USD (Million)
  • TABLE 101 Asia Rheumatology Arthritis Therapeutics Market By Biosimilars, 2020-2030, USD (Million)
  • TABLE 102 Asia Rheumatology Arthritis Therapeutics Market By Method of Administration, 2020-2030, USD (Million)
  • TABLE 103 Asia Rheumatology Arthritis Therapeutics Market By Mode of Sale, 2020-2030, USD (Million)
  • TABLE 104 Asia Rheumatology Arthritis Therapeutics Market By End User, 2020-2030, USD (Million)
  • TABLE 105 China Rheumatology Arthritis Therapeutics Market By Disease Type, 2020-2030, USD (Million)
  • TABLE 106 China Rheumatology Arthritis Therapeutics Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 107 China Rheumatology Arthritis Therapeutics Market By Pharmaceuticals, 2020-2030, USD (Million)
  • TABLE 108 China Rheumatology Arthritis Therapeutics Market By Biopharmaceuticals, 2020-2030, USD (Million)
  • TABLE 109 China Rheumatology Arthritis Therapeutics Market By Biosimilars, 2020-2030, USD (Million)
  • TABLE 110 China Rheumatology Arthritis Therapeutics Market By Method of Administration, 2020-2030, USD (Million)
  • TABLE 111 China Rheumatology Arthritis Therapeutics Market By Mode of Sale, 2020-2030, USD (Million)
  • TABLE 112 China Rheumatology Arthritis Therapeutics Market By End User, 2020-2030, USD (Million)
  • TABLE 113 Japan Rheumatology Arthritis Therapeutics Market By Disease Type, 2020-2030, USD (Million)
  • TABLE 114 Japan Rheumatology Arthritis Therapeutics Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 115 Japan Rheumatology Arthritis Therapeutics Market By Pharmaceuticals, 2020-2030, USD (Million)
  • TABLE 116 Japan Rheumatology Arthritis Therapeutics Market By Biopharmaceuticals, 2020-2030, USD (Million)
  • TABLE 117 Japan Rheumatology Arthritis Therapeutics Market By Biosimilars, 2020-2030, USD (Million)
  • TABLE 118 Japan Rheumatology Arthritis Therapeutics Market By Method of Administration, 2020-2030, USD (Million)
  • TABLE 119 Japan Rheumatology Arthritis Therapeutics Market By Mode of Sale, 2020-2030, USD (Million)
  • TABLE 120 Japan Rheumatology Arthritis Therapeutics Market By End User, 2020-2030, USD (Million)
  • TABLE 121 India Rheumatology Arthritis Therapeutics Market By Disease Type, 2020-2030, USD (Million)
  • TABLE 122 India Rheumatology Arthritis Therapeutics Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 123 India Rheumatology Arthritis Therapeutics Market By Pharmaceuticals, 2020-2030, USD (Million)
  • TABLE 124 India Rheumatology Arthritis Therapeutics Market By Biopharmaceuticals, 2020-2030, USD (Million)
  • TABLE 125 India Rheumatology Arthritis Therapeutics Market By Biosimilars, 2020-2030, USD (Million)
  • TABLE 126 India Rheumatology Arthritis Therapeutics Market By Method of Administration, 2020-2030, USD (Million)
  • TABLE 127 India Rheumatology Arthritis Therapeutics Market By Mode of Sale, 2020-2030, USD (Million)
  • TABLE 128 India Rheumatology Arthritis Therapeutics Market By End User, 2020-2030, USD (Million)
  • TABLE 129 Australia Rheumatology Arthritis Therapeutics Market By Disease Type, 2020-2030, USD (Million)
  • TABLE 130 Australia Rheumatology Arthritis Therapeutics Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 131 Australia Rheumatology Arthritis Therapeutics Market By Pharmaceuticals, 2020-2030, USD (Million)
  • TABLE 132 Australia Rheumatology Arthritis Therapeutics Market By Biopharmaceuticals, 2020-2030, USD (Million)
  • TABLE 133 Australia Rheumatology Arthritis Therapeutics Market By Biosimilars, 2020-2030, USD (Million)
  • TABLE 134 Australia Rheumatology Arthritis Therapeutics Market By Method of Administration, 2020-2030, USD (Million)
  • TABLE 135 Australia Rheumatology Arthritis Therapeutics Market By Mode of Sale, 2020-2030, USD (Million)
  • TABLE 136 Australia Rheumatology Arthritis Therapeutics Market By End User, 2020-2030, USD (Million)
  • TABLE 137 South Korea Rheumatology Arthritis Therapeutics Market By Disease Type, 2020-2030, USD (Million)
  • TABLE 138 South Korea Rheumatology Arthritis Therapeutics Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 139 South Korea Rheumatology Arthritis Therapeutics Market By Pharmaceuticals, 2020-2030, USD (Million)
  • TABLE 140 South Korea Rheumatology Arthritis Therapeutics Market By Biopharmaceuticals, 2020-2030, USD (Million)
  • TABLE 141 South Korea Rheumatology Arthritis Therapeutics Market By Biosimilars, 2020-2030, USD (Million)
  • TABLE 142 South Korea Rheumatology Arthritis Therapeutics Market By Method of Administration, 2020-2030, USD (Million)
  • TABLE 143 South Korea Rheumatology Arthritis Therapeutics Market By Mode of Sale, 2020-2030, USD (Million)
  • TABLE 144 South Korea Rheumatology Arthritis Therapeutics Market By End User, 2020-2030, USD (Million)
  • TABLE 145 Latin America Rheumatology Arthritis Therapeutics Market By Disease Type, 2020-2030, USD (Million)
  • TABLE 146 Latin America Rheumatology Arthritis Therapeutics Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 147 Latin America Rheumatology Arthritis Therapeutics Market By Pharmaceuticals, 2020-2030, USD (Million)
  • TABLE 148 Latin America Rheumatology Arthritis Therapeutics Market By Biopharmaceuticals, 2020-2030, USD (Million)
  • TABLE 149 Latin America Rheumatology Arthritis Therapeutics Market By Biosimilars, 2020-2030, USD (Million)
  • TABLE 150 Latin America Rheumatology Arthritis Therapeutics Market By Method of Administration, 2020-2030, USD (Million)
  • TABLE 151 Latin America Rheumatology Arthritis Therapeutics Market By Mode of Sale, 2020-2030, USD (Million)
  • TABLE 152 Latin America Rheumatology Arthritis Therapeutics Market By End User, 2020-2030, USD (Million)
  • TABLE 153 Brazil Rheumatology Arthritis Therapeutics Market By Disease Type, 2020-2030, USD (Million)
  • TABLE 154 Brazil Rheumatology Arthritis Therapeutics Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 155 Brazil Rheumatology Arthritis Therapeutics Market By Pharmaceuticals, 2020-2030, USD (Million)
  • TABLE 156 Brazil Rheumatology Arthritis Therapeutics Market By Biopharmaceuticals, 2020-2030, USD (Million)
  • TABLE 157 Brazil Rheumatology Arthritis Therapeutics Market By Biosimilars, 2020-2030, USD (Million)
  • TABLE 158 Brazil Rheumatology Arthritis Therapeutics Market By Method of Administration, 2020-2030, USD (Million)
  • TABLE 159 Brazil Rheumatology Arthritis Therapeutics Market By Mode of Sale, 2020-2030, USD (Million)
  • TABLE 160 Brazil Rheumatology Arthritis Therapeutics Market By End User, 2020-2030, USD (Million)
  • TABLE 161 Mexico Rheumatology Arthritis Therapeutics Market By Disease Type, 2020-2030, USD (Million)
  • TABLE 162 Mexico Rheumatology Arthritis Therapeutics Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 163 Mexico Rheumatology Arthritis Therapeutics Market By Pharmaceuticals, 2020-2030, USD (Million)
  • TABLE 164 Mexico Rheumatology Arthritis Therapeutics Market By Biopharmaceuticals, 2020-2030, USD (Million)
  • TABLE 165 Mexico Rheumatology Arthritis Therapeutics Market By Biosimilars, 2020-2030, USD (Million)
  • TABLE 166 Mexico Rheumatology Arthritis Therapeutics Market By Method of Administration, 2020-2030, USD (Million)
  • TABLE 167 Mexico Rheumatology Arthritis Therapeutics Market By Mode of Sale, 2020-2030, USD (Million)
  • TABLE 168 Mexico Rheumatology Arthritis Therapeutics Market By End User, 2020-2030, USD (Million)
  • TABLE 169 Rest of Latin America Rheumatology Arthritis Therapeutics Market By Disease Type, 2020-2030, USD (Million)
  • TABLE 170 Rest of Latin America Rheumatology Arthritis Therapeutics Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 171 Rest of Latin America Rheumatology Arthritis Therapeutics Market By Pharmaceuticals, 2020-2030, USD (Million)
  • TABLE 172 Rest of Latin America Rheumatology Arthritis Therapeutics Market By Biopharmaceuticals, 2020-2030, USD (Million)
  • TABLE 173 Rest of Latin America Rheumatology Arthritis Therapeutics Market By Biosimilars, 2020-2030, USD (Million)
  • TABLE 174 Rest of Latin America Rheumatology Arthritis Therapeutics Market By Method of Administration, 2020-2030, USD (Million)
  • TABLE 175 Rest of Latin America Rheumatology Arthritis Therapeutics Market By Mode of Sale, 2020-2030, USD (Million)
  • TABLE 176 Rest of Latin America Rheumatology Arthritis Therapeutics Market By End User, 2020-2030, USD (Million)
  • TABLE 177 Middle East and Africa Rheumatology Arthritis Therapeutics Market By Disease Type, 2020-2030, USD (Million)
  • TABLE 178 Middle East and Africa Rheumatology Arthritis Therapeutics Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 179 Middle East and Africa Rheumatology Arthritis Therapeutics Market By Pharmaceuticals, 2020-2030, USD (Million)
  • TABLE 180 Middle East and Africa Rheumatology Arthritis Therapeutics Market By Biopharmaceuticals, 2020-2030, USD (Million)
  • TABLE 181 Middle East and Africa Rheumatology Arthritis Therapeutics Market By Biosimilars, 2020-2030, USD (Million)
  • TABLE 182 Middle East and Africa Rheumatology Arthritis Therapeutics Market By Method of Administration, 2020-2030, USD (Million)
  • TABLE 183 Middle East and Africa Rheumatology Arthritis Therapeutics Market By Mode of Sale, 2020-2030, USD (Million)
  • TABLE 184 Middle East and Africa Rheumatology Arthritis Therapeutics Market By End User, 2020-2030, USD (Million)
  • TABLE 185 GCC Rheumatology Arthritis Therapeutics Market By Disease Type, 2020-2030, USD (Million)
  • TABLE 186 GCC Rheumatology Arthritis Therapeutics Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 187 GCC Rheumatology Arthritis Therapeutics Market By Pharmaceuticals, 2020-2030, USD (Million)
  • TABLE 188 GCC Rheumatology Arthritis Therapeutics Market By Biopharmaceuticals, 2020-2030, USD (Million)
  • TABLE 189 GCC Rheumatology Arthritis Therapeutics Market By Biosimilars, 2020-2030, USD (Million)
  • TABLE 190 GCC Rheumatology Arthritis Therapeutics Market By Method of Administration, 2020-2030, USD (Million)
  • TABLE 191 GCC Rheumatology Arthritis Therapeutics Market By Mode of Sale, 2020-2030, USD (Million)
  • TABLE 192 GCC Rheumatology Arthritis Therapeutics Market By End User, 2020-2030, USD (Million)
  • TABLE 193 Africa Rheumatology Arthritis Therapeutics Market By Disease Type, 2020-2030, USD (Million)
  • TABLE 194 Africa Rheumatology Arthritis Therapeutics Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 195 Africa Rheumatology Arthritis Therapeutics Market By Pharmaceuticals, 2020-2030, USD (Million)
  • TABLE 196 Africa Rheumatology Arthritis Therapeutics Market By Biopharmaceuticals, 2020-2030, USD (Million)
  • TABLE 197 Africa Rheumatology Arthritis Therapeutics Market By Biosimilars, 2020-2030, USD (Million)
  • TABLE 198 Africa Rheumatology Arthritis Therapeutics Market By Method of Administration, 2020-2030, USD (Million)
  • TABLE 199 Africa Rheumatology Arthritis Therapeutics Market By Mode of Sale, 2020-2030, USD (Million)
  • TABLE 200 Africa Rheumatology Arthritis Therapeutics Market By End User, 2020-2030, USD (Million)
  • TABLE 201 Rest of Middle East and Africa Rheumatology Arthritis Therapeutics Market By Disease Type, 2020-2030, USD (Million)
  • TABLE 202 Rest of Middle East and Africa Rheumatology Arthritis Therapeutics Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 203 Rest of Middle East and Africa Rheumatology Arthritis Therapeutics Market By Pharmaceuticals, 2020-2030, USD (Million)
  • TABLE 204 Rest of Middle East and Africa Rheumatology Arthritis Therapeutics Market By Biopharmaceuticals, 2020-2030, USD (Million)
  • TABLE 205 Rest of Middle East and Africa Rheumatology Arthritis Therapeutics Market By Biosimilars, 2020-2030, USD (Million)
  • TABLE 206 Rest of Middle East and Africa Rheumatology Arthritis Therapeutics Market By Method of Administration, 2020-2030, USD (Million)
  • TABLE 207 Rest of Middle East and Africa Rheumatology Arthritis Therapeutics Market By Mode of Sale, 2020-2030, USD (Million)
  • TABLE 208 Rest of Middle East and Africa Rheumatology Arthritis Therapeutics Market By End User, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Rheumatology Arthritis Therapeutics Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Rheumatology Arthritis Therapeutics Market: Quality Assurance
  • FIG. 5 Global Rheumatology Arthritis Therapeutics Market, By Disease Type, 2021
  • FIG. 6 Global Rheumatology Arthritis Therapeutics Market, By Drug Type, 2021
  • FIG. 7 Global Rheumatology Arthritis Therapeutics Market, By Method of Administration, 2021
  • FIG. 8 Global Rheumatology Arthritis Therapeutics Market, By Mode of Sale, 2021
  • FIG. 9 Global Rheumatology Arthritis Therapeutics Market, By End User, 2021
  • FIG. 10 Global Rheumatology Arthritis Therapeutics Market, By Geography, 2021
  • FIG. 11 Market Geographical Opportunity Matrix - Global Rheumatology Arthritis Therapeutics Market, 2021
  • FIG. 12 Market Positioning of Key Rheumatology Arthritis Therapeutics Market Players, 2021
  • FIG. 13 Global Rheumatology Arthritis Therapeutics Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
  • FIG. 14 Global Rheumatology Arthritis Therapeutics Market, By Disease Type, 2021 Vs 2030, %
  • FIG. 15 Global Rheumatology Arthritis Therapeutics Market, By Drug Type, 2021 Vs 2030, %
  • FIG. 16 Global Rheumatology Arthritis Therapeutics Market, By Method of Administration, 2021 Vs 2030, %
  • FIG. 17 Global Rheumatology Arthritis Therapeutics Market, By Mode of Sale, 2021 Vs 2030, %
  • FIG. 18 Global Rheumatology Arthritis Therapeutics Market, By End User, 2021 Vs 2030, %
  • FIG. 19 U.S. Rheumatology Arthritis Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 20 Canada Rheumatology Arthritis Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 21 Rest of North America Rheumatology Arthritis Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 22 UK Rheumatology Arthritis Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 23 Germany Rheumatology Arthritis Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 24 Spain Rheumatology Arthritis Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 25 Italy Rheumatology Arthritis Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 26 France Rheumatology Arthritis Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 27 Rest of Europe Rheumatology Arthritis Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 28 China Rheumatology Arthritis Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 29 Japan Rheumatology Arthritis Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 30 India Rheumatology Arthritis Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 31 Australia Rheumatology Arthritis Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 32 South Korea Rheumatology Arthritis Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 33 Rest of Asia Rheumatology Arthritis Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 34 Brazil Rheumatology Arthritis Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 35 Mexico Rheumatology Arthritis Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 36 Rest of Latin America Rheumatology Arthritis Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 37 GCC Rheumatology Arthritis Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 38 Africa Rheumatology Arthritis Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 39 Rest of Middle East and Africa Rheumatology Arthritis Therapeutics Market (US$ Million), 2020 - 2030